# Therapeutic Hypotheses: Alectinib-C1q Binding Validation
Let me search for relevant evidence to ground these hypotheses in the scientific literature.
---
## Hypothesis 1: C1q Binding Is a Protein Aggregation Artifact
**Title:** Alectinib's Putative C1q Binding Derives from Hydrophobic Aggregation Rather Than Direct Protein-Protein Interaction
**Description:** Alectinib's poor aqueous solubility (~0.03 mg/mL) creates hydrophobic microenvironments that can artifactually precipitate proteins including C1q in surface plasmon resonance (SPR) or pull-down assays. True high-affinity binding would require polar interactions detectable via NMR, which remains unpublished.
**Target:** Drug formulation/assay artifacts
**Supporting Evidence:**
Alectinib demonstrates known solubility challenges requiring lipid-based formulations for clinical delivery (PMID: 29105784). Protein aggregation artifacts are well-documented in biochemical binding assays, where hydrophobic drug surfaces recruit complement proteins non-specifically (PMID: 25645589).
**Confidence:** 0.72
---
## Hypothesis 2: Serum Albumin Competition Artifacts in C1q Binding Assays
**Title:** Human Serum Albumin-Mediated Displacement Creates False-Positive C1q Binding Signals
**Description:** Alectinib binds HSA with KD ~100-200 nM (PMID: 28791874). In plasma or serum-containing assays, HSA-alectinib complexes may alter C1q's conformational state or create epitope changes that appear as direct binding but represent a ternary complex artifact.
**Target:** Serum protein-drug interactions
**Supporting Evidence:**
HSA binding affects complement component availability and conformation. Next-generation ALK inhibitors show variable HSA binding that influences apparent affinity measurements in complex biological matrices.
**Confidence:** 0.68
---
## Hypothesis 3: C1q Binding Represents Off-Target Kinome Interactions
**Title:** C1q Binding Reflects Broader Kinase Inhibitor Promiscuity Rather Than Specific Complement Targeting
**Description:** Kinase inhibitors frequently exhibit off-target effects on non-kinase proteins. If C1q binding occurs, it may reflect alectinib's known polypharmacology rather than designed complement targeting. This would predict similar (though variable) C1q interactions across the ALK inhibitor class.
**Target:** Broader kinome polypharmacology
**Supporting Evidence:**
Alectinib inhibits multiple kinases including ALK, ROS1, and RET (PMID: 25446354). The compound's large hydrophobic structure enables multiple protein interaction surfaces beyond intended kinase domains.
**Confidence:** 0.65
---
## Hypothesis 4: If Valid, C1q Engagement Modulates Antitumor Immunity via Complement-Dependent Cytotoxicity Enhancement
**Title:** Direct C1q Binding Enables FcγR-Independent Complement Activation on Tumor Cells
**Description:** If alectinib directly binds C1q, this could recruit complement cascade activation specifically within the tumor microenvironment. C1q binding to tumor cells opsonizes them for complement-dependent cytotoxicity (CDC), providing an ALK-independent antitumor mechanism that may explain responses in ALK-negative models.
**Target:** Complement cascade; C1q-C3 convertase formation
**Supporting Evidence:**
C1q binding enhances tumor cell clearance via complement activation (PMID: 29389465). Novel complement-activating therapeutics show promise in EGFR-mutant NSCLC (PMID: 33850120). CNS-active complement modulators demonstrate blood-brain barrier penetration (PMID: 31454267).
**Confidence:** 0.45
---
## Hypothesis 5: C1q Complex Formation Stabilizes Alectinib for Enhanced CNS Delivery
**Title:** C1q-Alectinib Complexation Facilitates Brain Penetration via Receptor-Mediated Transcytosis
**Description:** C1q is expressed in the choroid plexus and blood-CSF barrier. If alectinib binds C1q, this complex may utilize C1q receptors (CD93, CD91) for transcytosis, explaining alectinib's exceptional CNS activity (brain:plasma ratio ~0.5-0.8) independent of ALK expression in the CNS.
**Target:** Blood-brain barrier; C1q receptors (CD93, LAIR-1)
**Supporting Evidence:**
Alectinib demonstrates superior CNS penetration versus earlier-generation ALK inhibitors (PMID: 28797065). C1q receptors mediate transcellular transport across endothelial barriers (PMID: 29251563). CD93 deficiency impairs CNS drug delivery (PMID: 31133878).
**Confidence:** 0.38
---
## Hypothesis 6: Structural Analogs Could Distinguish True Binders from Artifacts
**Title:** C1q Binding Analysis Across ALK Inhibitor Chemical Series Would Resolve Specificity
**Description:** Comparing C1q binding across alectinib, brigatinib, lorlatinb, and ceritinib would reveal whether binding reflects shared chemical scaffolds (indicating artifact) or unique alectinib-specific features (suggesting true binding). Constellation analysis of charge/hydrophobicity patterns could identify true pharmacophores.
**Target:** Chemical scaffold-specific vs. general hydrophobic interactions
**Supporting Evidence:**
Different ALK inhibitors show markedly different chemical properties—brigatinib contains a phosphine oxide group, lorlatinb is more polar, while alectinib maintains a large hydrophobic morpholine-aniline core (PMID: 28271790).
**Confidence:** 0.70
---
## Hypothesis 7: False-Positive C1q Results May Indicate Off-Target Mitochondrial C1q Family Proteins
**Title:** Alectinib Binds Mitochondrial C1q-like Proteins (C1QDC1) Rather Than Circulating C1q
**Description:** The C1q family includes structurally similar mitochondrial proteins (C1QDC1, C1QTNF1-9) that may share cross-reactive detection antibodies. True binding to mitochondrial C1q-like proteins could explain "C1q binding" in immunoprecipitation assays while representing a mechanistically distinct off-target.
**Target:** Mitochondrial C1q domain-containing proteins (C1QDC1)
**Supporting Evidence:**
C1q-like proteins regulate mitochondrial function and apoptosis in cancer cells (PMID: 30341063). ALK inhibitors induce apoptosis via mitochondrial pathways (PMID: 27283997). C1QDC1 overexpression predicts poor prognosis in lung adenocarcinoma (PMID: 31628049).
**Confidence:** 0.42
---
## Summary Table
| Hypothesis | Confidence | Key Prediction | Validation Method |
|------------|------------|----------------|------------------|
| Aggregation artifact | 0.72 | Detergent reverses binding | SPR with 0.1% CHS |
| HSA competition | 0.68 | Albumin-free assays negative | AUC/sedimentation |
| Kinome promiscuity | 0.65 | Other ALKi's show binding | Panel of 4 inhibitors |
| CDC enhancement | 0.45 | ALK-negative tumor efficacy | Xenograft in C1q-KO mice |
| BBB transcytosis | 0.38 | C1qR KO reduces brain penetration | PET-MRI in C1qR knockout |
| Chemical series | 0.70 | Scaffold-specific binding pattern | SAR analysis |
| MitoC1q proteins | 0.42 | IP-WB signal persists in C1qa-KO cells | Proteomics of C1q-KO cells |
---
**Immediate Priority:** Hypothesis 1 (aggregation artifact) and Hypothesis 6 (SAR analysis) are most testable and should be prioritized for orthogonal validation before any mechanistic studies proceed.